Methotrexát Denk (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition reduces the production of nucleotides needed for DNA, RNA and protein synthesis, thereby limiting the growth of rapidly dividing cells and dampening immune responses.

The specific dose and dosing schedule of Methotrexát Denk are determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Only a qualified healthcare professional should set the regimen.

Methotrexát Denk is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexát Denk shares the folate‑antagonist mechanism with other agents such as pemetrexed, but methotrexate has a broader range of approved indications, including autoimmune diseases. Its safety profile, dosing flexibility (including subcutaneous administration), and long‑standing clinical use make it a widely adopted option in many therapeutic areas.

Methotrexát Denk should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Maintaining the cold chain preserves drug stability and potency.

Methotrexát Denk is supplied as a sterile solution for subcutaneous injection. A qualified healthcare professional administers the dose using aseptic technique, typically into the abdomen or thigh, according to the prescriber’s instructions and local clinical guidelines.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to immunosuppression, bone‑marrow failure (aplastic anemia), acute renal impairment, and rare anaphylactic reactions. Patients should be monitored regularly for early signs of these complications.

Methotrexát Denk is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled renal impairment, active infections, or known hypersensitivity to methotrexate or any excipients. It should also be avoided in patients receiving live vaccines or certain interacting medications without close monitoring.